COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Graham, C. N. [1 ]
Hechmati, G. [2 ]
Hjelmgren, J. [2 ]
De Liege, F. [3 ]
Lanier, J. [3 ]
Knoof, A. [3 ]
Knox, H. [1 ]
Barber, B. [4 ]
de Pouvourville, G. [5 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen France SAS, Neuilly Sur Seine, France
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] ESSEC Business Sch, Cergy Pontoise, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：A632 / A632
页数：1
相关论文
共 50 条
  • [11] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Muro, K.
    Uetake, H.
    Tsuchihara, K.
    Shitara, K.
    Yamazaki, K.
    Ota, M.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Yamanaka, K.
    Mori, I.
    Soeda, J.
    Hihara, M.
    Yamanaka, T.
    Akagi, K.
    Ochiai, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [12] First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
    Rivera, F.
    Karthaus, M.
    Hecht, J. R.
    Fasola, G.
    Canon, J. -L.
    Koukakis, R.
    Demonty, G.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2015, 26
  • [13] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
    van Hazel, Guy A.
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget A.
    Strickland, Andrew H.
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan
    Boucher, Eveline
    Tichler, Thomas
    Shacham-Shmueli, Einat
    Powell, Alex
    Eliadis, Paul
    Isaacs, Richard
    Price, David
    Moeslein, Fred
    Taieb, Julien
    Bower, Geoff
    Gebski, Val
    Van Buskirk, Mark
    Cade, David N.
    Thurston, Kenneth
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
  • [14] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
  • [15] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [16] Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial
    Tang, Wentao
    Ren, Li
    Liu, Tianshu
    Ye, Qinghai
    Wei, Ye
    He, Guodong
    Lin, Qi
    Wang, Xiaoying
    Wang, Mingliang
    Liang, Fei
    Cui, Yuehong
    Xu, Jianmin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3175 - +
  • [17] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
  • [18] PANITUMUMAB+MFOLFOX6 VERSUS BEVACIZUMAB+MFOLFOX6 AS FIRST LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    dos Santos, R. F.
    Coutinho, M. B.
    Haas, L.
    VALUE IN HEALTH, 2015, 18 (07) : A821 - A821
  • [19] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    R P W Wong
    G D'Haens
    J-Y Douillard
    J Robertson
    A M Stone
    E Van Cutsem
    British Journal of Cancer, 2013, 108 : 493 - 502
  • [20] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    Cunningham, D.
    Wong, R. P. W.
    D'Haens, G.
    Douillard, J-Y
    Robertson, J.
    Stone, A. M.
    Van Cutsem, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 493 - 502
12345